Exploring the Untargeted Cysteinome of Protein Kinases

webinar

Thu, 09 Dec 2021, 16:30 CET (Berlin)

Prof. Dr. Matthias Gehringer, University of Tübingen, Germany

Exploring the Untargeted Cysteinome of Protein Kinases

Protein kinases are now among the major drug targets with over 65 inhibitors approved since the groundbreaking approval of imatinib (Gleevec) in 2001. Covalent targeting approaches that have gained traction in recent years, have proven particularly useful in the protein kinase field. Typically, covalent inhibitors feature superior potency and efficacy as well as a prolonged duration of action. Of the >500 human protein kinases, the so-called “kinome”, almost 50% are characterized by the presence of an accessible, non-conserved cysteine residue in or around the ATP binding site. Addressing such cysteines by mild electrophiles, termed covalent “warheads”, enables the rational design of highly potent and selective protein kinase inhibitors as chemical probes or drugs. So far, however, only a small fraction of the protein kinases’ “cysteinome” has been addressed. In this talk, Matthias will present recent efforts toward the development of covalent inhibitors for protein kinases with a cysteine in the so-called “hinge region” using canonical and non-canonical warhead chemistry. Specifically, he will focus on inhibitors targeting TTK/MPS1, a kinase controlling the spindle assembly checkpoint, and S6K2/p70S6Kβ, a neglected member of the ribosomal protein S6 kinase family. Join us!

Current news

category
Events
Recordings of the BioSolveIT Day 2025 Available
October 15, 2025 13:39 CEST
Missed BioSolveIT Day 2025? The recordings from BioSolveIT Day 2025 are now live! Packed with practical insights for medicinal and computational chemists, the sessions showcase how SeeSAR, infiniSee, Chemical Space Docking®, and CoLibri accelerate real-world discovery, from pocket-aware design and HYDE-guided decisions to trillion-scale, synthesizable chemical space exploration and in-house...
Read on
Enamine’s REAL Space September 2025 Update - Now 83 Billion!
September 23, 2025 10:31 CEST
The September 2025 update of Enamine’s REAL Space brings a new expansion, now featuring over 83 billion accessible, drug-like products, up from 76 billion in the previous release. Built from 172 curated reactions and 192,487 reagents and building blocks based on in-house knowledge, this version further enhances one of the...
Read on
WuXi’s GalaXi Space September 2025 – Expanded to 26 Billion Molecules!
September 17, 2025 10:03 CEST
The September 2025 update of WuXi LabNetwork’s GalaXi Space delivers a major expansion, now featuring over 25.8 billion synthesis-ready products. Built from 185 curated reactions and 30,877 high-quality building blocks, GalaXi is one of the largest tangible Chemical Spaces for modern drug discovery. This release broadens structural diversity with novel...
Read on